 |
|
Thalidomide as a Potential Treatment for Scleromyxedema
Stephanie Caradonna, MD;
Heidi Jacobe, MD
University of North Carolina, Chapel Hill
Arch Dermatol. 2004;140:277-280.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
REPORT OF A CASE
A 39-year-old African American woman was referred in April 1995 with a 1-year history of skin thickening. The process began on her hands and progressed to involve her arms, face, neck, shoulders, chest, and proximal extremities. Her only systemic complaints were limited mobility of her joints, particularly her hands and wrists. Physical examination findings revealed leonine facies. The skin of the neck, shoulders, and chest exhibited 1- to 2-mm coalescent linear papules. The skin of the hands, forearms, upper arms, and trunk was sclerotic. Skin biopsy results showed marked dermal thickening, displacement of collagen bundles by mucin, and numerous spindled fibroblasts, consistent with scleromyxedema. The results of laboratory tests, including a complete blood cell count, chemistry tests, liver function tests, an antinuclear antibody panel, an extractable nuclear antigen panel, and thyroid function tests, were normal. Immunoglobulins were obtained, and the following levels were revealed: . . . [Full Text of this Article]
THERAPEUTIC CHALLENGE
SOLUTION
COMMENT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Thalidomide for type 1 cryoglobulinemic vasculopathy.
Sampson and Callen
Arch Dermatol 2006;142:972-974.
FULL TEXT
Successful Treatment of Scleromyxedema With Autologous Peripheral Blood Stem Cell Transplantation
Lacy et al.
Arch Dermatol 2005;141:1277-1282.
ABSTRACT
| FULL TEXT
|
